Kai‐Keen Shiu
机构：University College Hospital, University College London · ORCID：0000-0001-6202-9640
发表论文 76 篇 · 总被引 5467 次 · h-index 20
代表论文
- Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study (2024 · Journal of Clinical Oncology · 被引 85)
- Adjuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): European Organisation of Research and Treatment of Cancer (EORTC) 1707 VESTIGE study (2024 · Annals of Oncology · 被引 49)
- NEOPRISM-CRC: Neoadjuvant pembrolizumab stratified to tumour mutation burden for high risk stage 2 or stage 3 deficient-MMR/MSI-high colorectal cancer. (2024 · Journal of Clinical Oncology · 被引 35)
- LBA-5 Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer (mCRC): the phase 3 LEAP-017 study (2023 · Annals of Oncology · 被引 27)
- Risk of bowel obstruction in patients with colon cancer responding to immunotherapy: an international case series (2024 · ESMO Open · 被引 21)
- Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study (2025 · Journal of Clinical Oncology · 被引 18)